Iqvia (NYSE:IQV) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $7.15-7.35 for the period, compared to the Thomson Reuters consensus estimate of $7.22. The company issued revenue guidance of 11.775-12.000 billion, compared to the consensus revenue estimate of $11.84 billion.Iqvia also updated its FY 2020
Pre-Market guidance to 7.15-7.35 EPS.
Shares of NYSE IQV traded down $1.47 during trading on Friday, reaching $164.32. 2,962,308 shares of the stock were exchanged, compared to its average volume of 1,312,776. The business’s 50-day moving average price is $157.99 and its 200 day moving average price is $151.69. Iqvia has a twelve month low of $130.77 and a twelve month high of $169.14. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 1.85. The company has a market capitalization of $31.03 billion, a price-to-earnings ratio of 134.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.91.
Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, February 12th. The medical research company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The business had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.85 billion. During the same period in the previous year, the company posted $1.50 earnings per share. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. As a group, sell-side analysts expect that Iqvia will post 5.9 earnings per share for the current fiscal year.
In other Iqvia news, Director Michael J. Evanisko sold 6,250 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $160.08, for a total transaction of $1,000,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael R. Mcdonnell sold 12,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $155.07, for a total transaction of $1,860,840.00. Following the sale, the chief financial officer now owns 14,366 shares of the company’s stock, valued at approximately $2,227,735.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,000 shares of company stock valued at $5,830,215. Insiders own 6.00% of the company’s stock.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.